Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.04

€1.04

1.310%
0.013
1.310%
€3.76

€3.76

 
22.12.25 / Tradegate WKN: A14SSK / Symbol: LXRX / Name: Lexicon PHARM / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€3.42
02.09.25
8.71%
buy
€3.45
24.06.25
64.74%
buy
21.04.25
86.91%
13.04.25
140.31%
05.04.25
190.74%
€3.71
28.03.25
82.97%
buy
Best running prediction
€3.81
03.03.25
196.02%
buy
Your prediction

Lexicon Pharmaceuticals Inc. Stock

Lexicon Pharmaceuticals Inc. gained 1.310% today.
Our community is currently high on Lexicon Pharmaceuticals Inc. with 6 Buy predictions and 3 Sell predictions.
With a target price of 3 € there is potential for a 187.91% increase which would mean more than doubling the current price of 1.04 € for Lexicon Pharmaceuticals Inc..
Our community identified positive and negative aspects for Lexicon Pharmaceuticals Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Lexicon Pharmaceuticals Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Lexicon Pharmaceuticals Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Lexicon Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Lexicon Pharmaceuticals Inc. 1.310% 2.458% -15.147% 31.982% 40.811% -40.647% -65.243%
Ardelyx Inc. -1.890% -0.081% 3.250% 11.858% -0.826% 131.663% -14.721%
Krystal Biotech 0.850% 7.068% 15.304% 39.043% 41.327% 190.676% -
Evolus Inc -2.480% -0.840% 2.609% -42.157% -43.810% -10.606% 81.204%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-28

Betrachtet man die Finanzdaten der Lexicon Pharmaceuticals, kann man sehen, dass das Unternehmen in einer komplexen finanziellen Situation steckt, die für Biotechnologie- und medizinische Forschungsunternehmen typisch ist. Da die meisten Unternehmen in dieser Branche sich auf Forschung und Entwicklung konzentrieren, sind hohe Kosten und Umsätze oft sehr variabel. Es scheint jedoch, dass Lexicon PHARM einige Herausforderungen zu bewältigen hat, wie die Analyse der bereitgestellten Finanzdaten zeigt.

Erstens ist das Unternehmen nachhaltig investiert, wie die hohen Beträge für Forschung und Entwicklung (R&D) zeigen. Investitionen in die Forschung sind für Unternehmen in der Biotechnologie und medizinischen Forschung von entscheidender Bedeutung, um innovative Produkte und Therapien zu entwickeln, die letztlich zu hohen Gewinnen führen können.

Zweitens hat Lexicon PHARM eine solide Bilanz mit erheblichen Beträgen an Vermögenswerten. Diese Vermögenswerte könnten das Unternehmen vor finanziellen Schwierigkeiten schützen und es könnte sie zur Finanzierung seiner fortlaufenden Forschungs- und Entwicklungsbemühungen nutzen.

Comments

Prediction Buy
Perf. (%) 8.71%
Target price 3.418
Change
Ends at 02.09.26

Lexicon Pharmaceuticals (NASDAQ:LXRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for LXRX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 64.74%
Target price 3.451
Change
Ends at 24.06.26

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for LXRX provided by MarketBeat
Show more

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for LXRX provided by MarketBeat
Show more